The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Subscribe To Our Newsletter & Stay Updated
